The START Center for Cancer Research Expands Its Capabilities to Support Early-Phase Hematological Cancer Trials
The START Center for Cancer Research Expands Its Capabilities to Support Early-Phase Hematological Cancer Trials
"Sites that combine expertise in hematological malignancies with experience in First-in-Human Phase 1 trials are relatively rare. Therefore, expanding our focus to include more blood cancer trials is a natural progression of our mission to provide access to patients globally," said Expansion Brings New Principal Investigators, Expanded Site Resources, and Accelerated Trial Initiation to Support Breakthrough Blood Cancer Therapies
擴展帶來了新的主要研究者、擴展的現場資源，以及加速試驗啓動，以支持突破性的血液癌症療法
SAN ANTONIO, Dec. 10, 2024 /PRNewswire/ -- The START Center for Cancer Research ("START"), the world's largest community-based early phase cancer trial site network, has announced the expansion of its capabilities to support early phase hematological cancer trials globally. This expansion includes the addition of leading Principal Investigators and clinical staff, growth in site capabilities including advanced laboratory infrastructure and specialized equipment, and the advancement of physician practice and hospital partnerships to increase access to patients in need of clinical trial options.
聖安東尼奧，2024年12月10日 /PRNewswire/ -- STARt抗癌醫藥中心（"START"），全球最大基於社區的早期階段癌症試驗地點網絡，已宣佈擴展其能力，以支持全球早期階段的血液腫瘤試驗。此次擴展包括新增領先的主要研究者和臨床工作人員，現場能力的增長，包括先進的製造行業和專業設備，以及推進醫生實踐和醫院合作伙伴關係，以增加對需要臨床試驗期權患者的訪問。
With the significant growth in new hematological cancer trials, pharmaceutical companies are challenged to find early phase clinical trial sites equipped to quickly open and enroll patients. To meet this demand, START brings unmatched expertise to hematological cancer research, led by distinguished Principal Investigators Dr. Andrew Sochacki (START Midwest), Dr. Daniel Morillo (START Madrid FJD), Dr. Gala Vega (START Madrid FJD) and Dr. Damián Cubilla (START CIOCC). Over the past five years, START has conducted more than 70 malignant hematology trials, enrolling over 250 patients.
隨着新的血液腫瘤試驗的顯著增長，藥品公司面臨着尋找能夠迅速啓動並招募患者的早期階段臨床試驗網站的挑戰。爲了滿足這一需求，STARt在血液腫瘤研究中帶來了無與倫比的專業知識，由傑出的主要研究者安德魯·索查基博士（STARt Midwest）、丹尼爾·莫里略博士（STARt 馬德里 FJD）、加拉·維加博士（STARt 馬德里 FJD）和達米安·庫比拉博士（STARt CIOCC）領導。在過去五年中，STARt進行了70多項惡性血液病試驗，招募了超過250名患者。
"Sites that combine expertise in hematological malignancies with experience in First-in-Human Phase 1 trials are relatively rare. Therefore, expanding our focus to include more blood cancer trials is a natural progression of our mission to provide access to patients globally," said Nick Slack, MBE, Chairman and CEO of START. "We are building on our strong foundation of conducting hematological trials with world-class investigators and trusted pharmaceutical partners. As the demand for innovative support in hematologic cancers grows, we are proud to bring our expertise forward to meet this critical need. Our goal is to address the unique challenges of these diseases while delivering the operational excellence and scientific rigor that accelerates the availability of therapies."
「結合血液惡性腫瘤專業知識與第一人類I期試驗經驗的網站相對較少。因此，將我們的重點擴展到更多血液癌症試驗是我們使命的自然進展，目的是爲全球患者提供獲取機會，」STARt董事長兼首席執行官Nick Slack，MBE說。「我們正建立在與國際一流的研究者和受信任的藥品合作伙伴共同進行血液試驗的堅實基礎之上。隨着對血液腫瘤的創新支持需求的增長，我們很自豪能帶來我們的專業知識，以滿足這一關鍵需求。我們的目標是解決這些疾病的獨特挑戰，同時提供加速療法可用性的運營卓越性和科學嚴謹性。」
START has a strong history of success in early-phase blood cancer therapies, including CAR T-cell treatments and cellular immunotherapies. The expanded focus on hematological cancers will enable START to offer sponsors even more comprehensive support, such as a streamlined protocol review process and accelerated trial initiation. With over 40 active early-phase hematology trials currently underway, START combines its depth of clinical experience with innovative operational processes to serve as a strong foundation for further expansion.
STARt 在早期血癌治療方面擁有強大的成功歷史，包括CAR T細胞治療和細胞免疫療法。對血液癌症的重點擴展將使STARt能夠爲贊助商提供更全面的支持，例如流暢的方案審查流程和加速的試驗啓動。目前有超過40個活躍的早期血液學臨床試驗正在進行中，STARt將其深厚的臨床經驗與創新的運營流程相結合，爲進一步擴展奠定了堅實的基礎。
"We are proud to deepen our focus in advancing hematological cancer treatments," remarked Chris Takimoto, MD, PhD, Chief Medical Officer at START. "This expansion reflects our commitment to transforming the clinical trial landscape through clinical innovation and collaboration, helping our pharmaceutical partners bring more care options to patients faster and more effectively."
"我們很自豪能夠加深我們在推進血液癌症治療方面的關注，" STARt的首席醫療官Chris Takimoto博士說道。"這一擴展體現了我們通過臨床創新和合作改變臨床試驗格局的承諾，幫助我們的藥品合作伙伴更快、更有效地爲患者提供更多護理選擇。"
Patients with blood cancers often face limited options and uncertain outcomes. By integrating clinical trials into community settings, START ensures that patients receive care close to home, where they are supported by both their local care teams and research opportunities. This expansion reaffirms START's role as a global leader in oncology innovation.
血癌患者往往面臨有限的選擇和不確定的結果。通過將臨床試驗整合到社區環境中，STARt確保患者在家附近接受護理，並獲得當地護理團隊和研究機會的支持。這一擴展重申了STARt作爲抗癌創新全球領導者的角色。
About The START Center for Cancer Research
關於STARt抗癌研究中心
The START Center for Cancer Research is deeply integrated with community oncology centers worldwide, providing unique access to early-stage clinical trials for new anti-cancer drugs. Our clinical trial sites have led over a thousand early-phase trials, contributing to the FDA or EMA approval of 43 therapies. With ongoing investment in our team of Principal Investigators and capabilities, we are dedicated to expediting the journey from trials to treatments, bringing hope to patients, families, and healthcare providers globally. Explore more at STARTresearch.com.
STARt抗癌研究中心與全球的社區腫瘤醫院深度整合，爲新抗癌藥物的早期臨床試驗提供獨特的機會。我們的臨床試驗網站已主導了超過一千個早期試驗，促進了43個療法的FDA或EMA批准。我們正在持續投資於我們的主要研究員團隊和能力，致力於加快從試驗到治療的過程，給全球的患者、家庭和醫療服務提供者帶來希望。更多信息請訪問STARt研究網站。
Contact:
Lauren Panco
1-609-216-4920
[email protected]
聯繫：
勞倫·潘科
1-609-216-4920
[email protected]
SOURCE The START Center for Cancer Research
來源於抗癌醫藥的STARt中心
